<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Replimune Group Inc — News on 6ix</title>
<link>https://6ix.com/company/replimune-group-inc</link>
<description>Latest news and press releases for Replimune Group Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/replimune-group-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b6e578dffbe2df11449f.webp</url>
<title>Replimune Group Inc</title>
<link>https://6ix.com/company/replimune-group-inc</link>
</image>
<item>
<title>Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-to-present-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-to-present-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting</guid>
<pubDate>Mon, 27 Apr 2026 12:00:00 GMT</pubDate>
<description>WOBURN, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2026. The Company has two abstracts selected for oral presentation, including a 3-year landmark overall survival analysis from the IGNYTE clinical trial of R</description>
</item>
<item>
<title>Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-receives-complete-response-letter-from-the-fda-for-rp1-biologics-license-application-for-the-treatment-of-advanced-melanoma</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-receives-complete-response-letter-from-the-fda-for-rp1-biologics-license-application-for-the-treatment-of-advanced-melanoma</guid>
<pubDate>Fri, 10 Apr 2026 04:00:00 GMT</pubDate>
<description>WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of</description>
</item>
<item>
<title>Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-reports-fiscal-third-quarter-2026-financial-results-and-provides-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-reports-fiscal-third-quarter-2026-financial-results-and-provides-corporate</guid>
<pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
<description>April 10, 2026 Target Action Date for RP1 in Advanced Melanoma WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a</description>
</item>
<item>
<title>Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-present-44th-annual-jp-morgan-healthcare-conference-2025-12-18</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-present-44th-annual-jp-morgan-healthcare-conference-2025-12-18</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of</description>
</item>
<item>
<title>Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-presents-late-breaking-abstract-and-additional-posters-rp1-40th-annual</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-presents-late-breaking-abstract-and-additional-posters-rp1-40th-annual</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following</description>
</item>
<item>
<title>Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-reports-fiscal-second-quarter-2026-financial-results-and-provides-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-reports-fiscal-second-quarter-2026-financial-results-and-provides-corporate</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of</description>
</item>
<item>
<title>Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-announces-fda-acceptance-bla-resubmission-rp1-treatment-advanced-melanoma</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-announces-fda-acceptance-bla-resubmission-rp1-treatment-advanced-melanoma</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc.</description>
</item>
<item>
<title>Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-highlights-acral-melanoma-data-rp1-plus-nivolumab-esmo-congress-2025-2025</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-highlights-acral-melanoma-data-rp1-plus-nivolumab-esmo-congress-2025-2025</guid>
<pubDate>Sun, 19 Oct 2025 04:00:00 GMT</pubDate>
<description>WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of</description>
</item>
<item>
<title>Replimune Provides Update Following Type A Meeting with FDA</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-provides-update-following-type-meeting-fda-2025-09-18</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-provides-update-following-type-meeting-fda-2025-09-18</guid>
<pubDate>Thu, 18 Sep 2025 04:00:00 GMT</pubDate>
<description>WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of</description>
</item>
<item>
<title>Replimune Announces Type A Meeting Scheduled with FDA</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-announces-type-meeting-scheduled-fda-2025-09-02</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-announces-type-meeting-scheduled-fda-2025-09-02</guid>
<pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
<description>WOBURN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of</description>
</item>
<item>
<title>Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-reports-fiscal-first-quarter-2026-financial-results-and-provides-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-reports-fiscal-first-quarter-2026-financial-results-and-provides-corporate</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of</description>
</item>
<item>
<title>Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-receives-complete-response-letter-fda-rp1-biologics-license-application</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-receives-complete-response-letter-fda-rp1-biologics-license-application</guid>
<pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
<description>WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of</description>
</item>
<item>
<title>Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-07-11</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-07-11</guid>
<pubDate>Fri, 11 Jul 2025 04:00:00 GMT</pubDate>
<description>WOBURN, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of</description>
</item>
<item>
<title>Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-presents-new-analyses-ignyte-study-rp1-plus-nivolumab-anti-pd1-failed</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-presents-new-analyses-ignyte-study-rp1-plus-nivolumab-anti-pd1-failed</guid>
<pubDate>Sun, 01 Jun 2025 04:00:00 GMT</pubDate>
<description>- RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung,</description>
</item>
<item>
<title>Replimune to Present at the 2025 Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-present-2025-jefferies-global-healthcare-conference-2025-05-29</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-present-2025-jefferies-global-healthcare-conference-2025-05-29</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>WOBURN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of</description>
</item>
<item>
<title>Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-reports-fiscal-fourth-quarter-and-year-end-2025-financial-results-and</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-reports-fiscal-fourth-quarter-and-year-end-2025-financial-results-and</guid>
<pubDate>Thu, 22 May 2025 04:00:00 GMT</pubDate>
<description>• BLA priority review of RP1 plus nivolumab in advanced melanoma proceeding on schedule; manufacturing inspections and late cycle review meeting complete •</description>
</item>
<item>
<title>Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-announces-dates-fiscal-fourth-quarter-and-year-end-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-announces-dates-fiscal-fourth-quarter-and-year-end-2025-financial-results</guid>
<pubDate>Fri, 16 May 2025 04:00:00 GMT</pubDate>
<description>WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of</description>
</item>
<item>
<title>Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-05-09</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-05-09</guid>
<pubDate>Fri, 09 May 2025 04:00:00 GMT</pubDate>
<description>WOBURN, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of</description>
</item>
<item>
<title>Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-03-07</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-03-07</guid>
<pubDate>Fri, 07 Mar 2025 05:00:00 GMT</pubDate>
<description>WOBURN, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of</description>
</item>
<item>
<title>Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/replimune-group-inc/news/replimune-reports-fiscal-third-quarter-2025-financial-results-and-provides-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/replimune-group-inc/news/replimune-reports-fiscal-third-quarter-2025-financial-results-and-provides-corporate</guid>
<pubDate>Wed, 12 Feb 2025 05:00:00 GMT</pubDate>
<description>U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority</description>
</item>
</channel>
</rss>